力尔凡发热寒战反应观察及其预防  

Fever,Rigor Reaction of the α-Manman Peptide (Lifein) and Their Precaution

作　　者：陈丽容[1] 姚和瑞[1] 谢德荣[1] 陈岱佳[1] 梁佩仲[1] 谢雪霞[1] 

机构地区：[1]中山医科大学孙逸仙纪念医院肿瘤科,广州510120

出　　处：《实用护理杂志》1999年第6期10-11,共2页Journal of Practical Nursing

摘　　要：目的：了解恶性肿瘤患者使用抗肿瘤新药力尔凡发热、寒战等反应的发生情况及预防方法。方法：随机分为２ 组， Ａ 组使用力尔凡前未预防性使用消炎痛， Ｂ 组于使用力尔凡前予消炎痛２５ ｍｇ 口服；给药途径随机分静脉滴注及肌肉注射。每一患者每次应用力尔凡均作１ 例次统计，观察每例次发热、寒战的发生情况，比较不同组别反应发生率的差异。结果：预防性用药反应发生率明显低于未预防性用药；肌肉注射反应发生率与静脉滴注无显著差异。结论：使用力尔凡前预防性应用消炎痛，有助于降低发热、寒战等反应的发生率，使患者更好地配合治疗。Objective:To observe the fever,rigor reaction of the α-Manman Peptide (Lifein) and the precaution.Methods:The patients were randomly divided into two groups.They were assigned to receive either contral or indomethacin before administration of Lifein,and the Lifein were given by intramuscular injection or intravenous drip randomly.Observed the fever,rigor reaction for every administration.Compared the difference of these reactions in each groups.Results:The reation rate of prevented administration were much lower than not prevented administration.But no difference was found between intramuscular injection or intravenous drip.Conclusion:Precautionary administration of indomethacin is useful for preventing the fever,rigor reaction of Lifein.\;

关 键 词：力尔凡 药物反应 预防 抗癌药 发热 寒战反应 

分 类 号：R979.1[医药卫生—药品]